Floatz logo

Tafasitamab

Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

David Bond, MDmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Northwestern University
Phase 2/3BB
Inno-206
Ruijin Hospital
Phase 2/3BB
PREDNISONE TABLETS
Ruijin Hospital
Phase 2/3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Ruijin Hospital
Phase 2/3BB
Cyclophosphamide
Ruijin Hospital
Phase 2/3BB

View all 32 →

Same molecule, other indications

Tafasitamab is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
high grade B-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →